Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemetrexed - Eli Lilly and Company

Drug Profile

Pemetrexed - Eli Lilly and Company

Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multitargeted antifolate; Pemetrexed disodium

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; John Wayne Cancer Institute; Merck Sharp & Dohme; University of California, Davis; Virginia Commonwealth University
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer
  • Phase I/II Solid tumours
  • Phase I Chordoma
  • No development reported Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
  • Discontinued Small cell lung cancer

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 06 Sep 2019 Phase-I clinical trials in Chordoma in USA (IV) (NCT03955042)
  • 31 Jan 2019 The US FDA approves pemetrexed for Non small cell lung cancer with no EGFR or ALK genomic tumor aberrations (First-line therapy, Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top